Palisade Bio Highlights PALI-2108 Potential for Fibrostenotic Crohn’s Disease at NYAS Symposium
Event summary
- Palisade Bio’s Mitchell Jones, MD, PhD, to present on PALI-2108 for fibrostenotic Crohn’s disease at NYAS symposium on June 9, 2026.
- Presentation focuses on unmet needs in fibrostenotic Crohn’s disease and the potential of locally bioactivated PDE4 inhibitor prodrugs.
- PALI-2108 has shown positive results in Phase 1a and two Phase 1b clinical trials, including studies in ulcerative colitis and FSCD.
- Company advancing towards Phase 2 clinical studies in ulcerative colitis and Crohn’s disease.
The big picture
Palisade Bio’s presentation at the NYAS symposium underscores the growing focus on targeted therapies for fibrotic diseases, particularly in Crohn’s disease where fibrosis remains a significant unmet need. The company’s prodrug platform aims to improve upon existing PDE4 inhibitors by enhancing pharmacology and tolerability, positioning it within a competitive landscape of biopharmaceutical firms developing next-generation treatments for chronic inflammatory conditions.
What we're watching
- Clinical Progress
- The pace at which PALI-2108 advances through Phase 2 trials will determine its viability as a therapeutic option for fibrostenotic Crohn’s disease.
- Market Differentiation
- Whether Palisade Bio can position PALI-2108 as a superior alternative to existing treatments for inflammatory and fibrotic diseases.
- Regulatory Pathway
- How the company navigates regulatory approvals for a novel therapeutic approach in a disease area with no approved therapies.
Related topics